Imbria Pharmaceuticals

Imbria is a privately held, clinical stage company developing therapies for cardiometabolic disorders. 

two ways to win two goals target arrow multiple
Biotech

Imbria hits goal in angina trial days after heart failure win

The cardiometabolic biotech reported phase 2 primary endpoint hits for one candidate in two heart disease settings in quick succession.
Nick Paul Taylor Nov 13, 2023 6:10am
heart disease AKG monitor flatline pulse AFIB

Imbria hits safety benchmark in phase 2 heart failure test

Nov 7, 2023 9:55am